Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide for prevention of CAR-T neurotoxicity in DLBCL
NCT03954106Phase 2Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of defibrotide in immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Incidence of CAR-T-associated Neurotoxicity of Any Grade Defined by CTCAE v5.0. Started Oct 2019; status: terminated.
02
Drugs
defibrotide
03
Conditions
immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT03954106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954106.